This liquid pharmaceutical preparation for subcutaneous administration in humans contains 28.2 µg of teriparatide or salt thereof (component 1) in terms of teriparatide in a single dose, wherein the concentration of component 1 is 80 to 240 µg/mL. This liquid pharmaceutical preparation has excellent pharmacodynamics.